海思科(002653) - 2023 Q2 - 季度财报

Financial Performance - Revenue for the reporting period was RMB 1,369,698,088.21, a year-on-year increase of 9.81%[13] - Net profit attributable to shareholders of the listed company was RMB 75,075,253.96, a year-on-year increase of 7.52%[13] - Net cash flow from operating activities was RMB 55,296,303.29, a significant increase of 202.64% compared to the same period last year[13] - Total assets at the end of the reporting period were RMB 6,411,183,425.32, an increase of 6.01% compared to the end of the previous year[13] - Net assets attributable to shareholders of the listed company were RMB 3,971,327,318.19, a year-on-year increase of 30.83%[13] - Basic earnings per share were RMB 0.0679, an increase of 4.62% compared to the same period last year[13] - Weighted average return on equity was 1.99%, a decrease of 0.42 percentage points compared to the same period last year[13] - Revenue for the first half of 2023 reached 1.37 billion yuan, a year-on-year increase of 9.81%[25] - Total operating revenue for the first half of 2023 reached 1,369,698,088.21 yuan, a 9.8% increase compared to 1,247,346,556.30 yuan in the same period last year[156] - Net profit attributable to the parent company's shareholders was 75,075,253.96 yuan, up 7.5% from 69,822,217.46 yuan in the first half of 2022[158] - Net profit for the first half of 2023 was RMB 142,118,726.69, a significant increase compared to RMB 84,426,517.16 in the same period last year[160] - Operating cash flow for the first half of 2023 was RMB 55,296,303.29, a positive turnaround from a negative RMB 53,873,397.17 in the same period last year[162] - Sales revenue from goods and services in the first half of 2023 was RMB 1,632,546,550.25, up from RMB 1,281,113,171.35 in the same period last year[162] - Investment cash outflow for the first half of 2023 was RMB 397,907,096.19, slightly higher than RMB 387,247,396.17 in the same period last year[163] - Financing cash inflow for the first half of 2023 was RMB 1,299,101,640.51, a decrease from RMB 1,485,482,318.96 in the same period last year[163] - Cash and cash equivalents at the end of the first half of 2023 were RMB 1,193,484,371.25, up from RMB 1,056,687,105.83 at the end of the same period last year[163] - Interest expenses for the first half of 2023 were RMB 18,782,291.93, compared to RMB 13,092,338.72 in the same period last year[160] - Credit impairment loss for the first half of 2023 was RMB -20,806,273.30, a significant increase compared to RMB -2,252,100.18 in the same period last year[160] - Total comprehensive income for the first half of 2023 was RMB 136,700,749.54, down from RMB 210,212,732.83 in the same period last year[161] - The company received RMB 793,640,000.00 from equity financing in the first half of 2023, a substantial increase compared to RMB 300,817.80 in the same period last year[163] - Operating cash flow from sales of goods and services increased to 1,618,967,826.94 yuan in H1 2023, up 26.1% from 1,283,709,993.50 yuan in H1 2022[164] - Net cash flow from operating activities improved to -306,269,605.97 yuan in H1 2023, compared to -334,444,146.29 yuan in H1 2022[164] - Net cash flow from investing activities turned positive at 31,325,828.08 yuan in H1 2023, a significant improvement from -109,751,211.74 yuan in H1 2022[165] - Net cash flow from financing activities increased to 741,048,893.76 yuan in H1 2023, up 23% from 602,764,291.94 yuan in H1 2022[165] - Cash and cash equivalents at the end of H1 2023 stood at 579,380,273.70 yuan, a 70.8% increase from 339,115,976.39 yuan at the end of H1 2022[165] - Total equity attributable to owners of the parent company increased to 3,035,744,121.70 yuan in H1 2023, up from 2,997,233,240.09 yuan at the end of 2022[166] - Comprehensive income for H1 2023 was 147,921,098.39 yuan, compared to 147,623,486.24 yuan in H1 2022[167] - Capital raised from owners' investments in H1 2023 totaled 795,306,691.83 yuan, including 790,866,217.57 yuan from issuance of ordinary shares[167] - Other comprehensive income transferred to retained earnings decreased by 52,576,578.37 yuan[168] - Special reserve for the period amounted to 5,200,758.65 yuan[168] - Extraction of special reserve for the period was 7,533,880.17 yuan[168] - Usage of special reserve for the period was 2,333,121.52 yuan[168] - Other items resulted in a decrease of 12,683,667.11 yuan[168] - Total comprehensive income for the period was 111,223,289.03 yuan[170] - Owner's equity decreased by 1,078,750.00 yuan due to capital reduction[170] - Profit distribution resulted in a decrease of 214,568,345.67 yuan[170] - Special reserve for the period amounted to 2,629,665.77 yuan[171] - Extraction of special reserve for the period was 3,423,566.96 yuan[171] - The company's total owner's equity at the end of the period was 4,151,867,526.77 yuan, an increase of 982,159,382.94 yuan compared to the beginning of the period[172] - Comprehensive income for the period was 199,536,358.21 yuan, with net profit attributable to owners of 142,118,726.69 yuan[172] - Capital reserve increased by 748,633,731.84 yuan, mainly due to the issuance of new shares[172] - Undistributed profits increased by 187,255,474.09 yuan, reflecting the company's profitability[172] - The company issued 40,000,000 new shares, raising 790,866,217.58 yuan[172] - Share-based payment expenses amounted to 4,440,474.26 yuan[172] - Other comprehensive income decreased by 5,417,977.15 yuan, mainly due to changes in fair value of financial assets[172] - The company's total owner's equity at the beginning of the period was 3,169,708,143.83 yuan[172] - The company's share capital increased by 38,510,500.00 yuan due to the issuance of new shares[172] - The company's capital reserve at the beginning of the period was 56,011,510.69 yuan[172] R&D and Innovation - R&D investment in the first half of 2023 was 372 million yuan, a year-on-year increase of 7.25%, accounting for 27.15% of revenue[25] - The company's self-developed 1.1 class innovative intravenous anesthetic, ciprofol injection, has been approved in China and is in the top 3 in the domestic market[23] - The company's diabetes peripheral neuropathy drug HSK16149 and type 2 diabetes treatment drug HSK7653 have submitted NDAs and are under review[24] - The company's innovative drug HSK3486 (ciprofol injection) is undergoing phase III clinical trials in the US and is expected to be launched in the US within the next 2 years[24] - The company's clinical trials are conducted in accordance with international standards, with self-built clinical and operational teams ensuring compliance and data quality[19] - The company's innovative drugs HSK16149 and HSK7653 were presented at the ADA global diabetes conference, receiving international recognition[22] - The company has 44 R&D projects in progress, including 23 innovative drugs (19 Class 1, 3 Class 2, and 1 Class 5.1), 20 generic drugs, and 1 medical device, covering 4 therapeutic areas[26] - In the first half of 2023, the company filed 154 patent applications, with 20 granted, and applied for 4 new trademarks, with 31 approved[26] - The company's HSK31679 tablet received a clinical approval for non-alcoholic steatohepatitis in June 2023[27] - HSK38008 oral formulation received clinical approval for prostate cancer in April 2023[27] - HSK40118 tablet received clinical approval for advanced non-small cell lung cancer in March 2023[27] - The company's HSK3486 (anesthetic induction) achieved the primary endpoint in its first US Phase III trial, with a second Phase III trial ongoing and a third planned for 2023 in the US and Europe[29] - The company's HSK7653 (long-acting hypoglycemic drug) submitted an NDA in January 2023, currently under review[29] - HSK21542 (postoperative analgesia) recently submitted an NDA, with Phase III trials for chronic kidney disease pruritus progressing well[29] - The company plans to advance 2-3 innovative drugs to IND application in the second half of 2023, focusing on oncology and analgesia[36] - The company aims to initiate 3-5 new projects in the second half of 2023 to expand its product pipeline[36] - HSK7653, a treatment for type 2 diabetes, has submitted an NDA application and is in preparation for market launch[35] - HSK16149, a treatment for diabetic peripheral neuropathy, has submitted an NDA application and is preparing for market launch, with its indication for postherpetic neuralgia completing Phase III trials and preparing for NDA submission[35] - HSK21542, a postoperative analgesic, has recently submitted an NDA application, and its tablet form has completed IND application and is expected to receive clinical approval soon[35] - HSK34890, a treatment for type 2 diabetes, submitted an IND application in May 2023 and received clinical trial approval in August 2023[35] - HSK29116, a treatment for refractory B-cell lymphoma, HSK40118 for advanced non-small cell lung cancer, and HSK38008 for prostate cancer are all in Phase I clinical trials[35] - HSK31858, a treatment for non-cystic bronchiectasis, is advancing Phase II clinical trials, while HL231 for COPD has completed Phase II and is preparing for Phase III trials[35] - The company has 777 Chinese patents, 35 US patents, and 171 PCT patents, with 198 Chinese patents and 12 US patents already granted[40] - The company has established a comprehensive technology system from early drug discovery to commercialization, including platforms like Protac and PDC, which enhance drug development efficiency[39] - R&D expenses increased to 209,474,983.33 yuan, a 16.2% rise compared to 180,216,180.53 yuan in the first half of 2022[157] - The company has undertaken 6 national-level research projects as of June 30, 2023[44] - The company has published nearly 40 papers in core journals, focusing on anesthesia, analgesia, and diabetes[44] - The R&D team consists of over 800 personnel, with 39% holding master's degrees or higher[45] - The chemical team includes over 100 researchers, with 73% holding master's degrees or higher[46] - The biological team has developed multiple international innovation platforms, including target validation and screening platforms[46] - The company has approximately 30 projects in the screening stage, targeting areas such as oncology, autoimmune, respiratory, and ophthalmology[47] Market and Sales Performance - The company's innovative drug, Ciprofol Injection, achieved sales revenue of approximately 340 million yuan in the first half of 2023, with a market share increase from 2.33% in Q1 2022 to 8.39% in Q1 2023[17] - Dolasetron Mesylate Injection (Libifu) maintained a market share of around 8% in H1 2023, with a smooth transition from agency to direct sales model[17] - Polyene Phosphatidylcholine Injection (Sifu) saw a market share increase to 10.8% in April-May 2023, up 31.6% from the previous period, covering 4,274 hospital terminals[17] - Methylprednisolone Sodium Succinate for Injection (Siwu) held a 42.68% market share in systemic glucocorticoids in 2022, with Siwu accounting for 8.2% of the Methylprednisolone Injection market, growing by 80.3%[18] - Flupentixol and Melitracen Tablets (Lepan) captured a 4.15% market share in 2022, ranking third in its product category[18] - The company's marketing center achieved its goals, with the market share of innovative drugs increasing, and the sales of ciprofol injection reaching a record high of 900,000 units in June 2023[30] - Total operating revenue increased by 9.81% YoY to RMB 1,369,698,088.21, with the pharmaceutical industry contributing 99.33% of the revenue[50] - Anesthesia products revenue surged by 165.71% YoY to RMB 342,656,667.79, accounting for 25.02% of total revenue[50] - Revenue from the Eastern region grew by 37.89% YoY to RMB 200,319,254.36, while the Western region declined by 6.19% YoY to RMB 451,912,919.29[50] - The company's gross margin for the pharmaceutical industry improved by 2.19% YoY to 71.54%[52] Production and Operations - The company's production model is mainly self-production, supplemented by cooperative production, with four production bases in Liaoning and Sichuan[21] - The company's marketing system includes a professional academic promotion model and a full-channel marketing model, covering both in-hospital and out-of-hospital channels[20] - The company's production capacity is supplemented by a new production base in Shannan, Tibet[21] - The company's total production of formulations and APIs increased by 18% year-over-year, with 3,730 million bottles/bags produced in Liaoning and 13,010.39 million tablets/capsules produced in Meishan[32][34] - The company invested RMB 956,392.66 in the construction of the Tibet Pharmaceutical Factory during the reporting period, with a cumulative investment of RMB 67,714,549.77 and a project progress of 99%[60] - The company's financial assets at the end of the period totaled RMB 240,932,227.19, with a decrease of RMB 236,191,488.32 due to factors such as the recovery of principal from wealth management products and a reduction in receivables financing[56] - The company's other equity instrument investments decreased by RMB 3,441,551.35, resulting in a final balance of RMB 212,053,410.19[56] - The company's receivables financing decreased by RMB 32,749,936.97, with a final balance of RMB 28,878,817.00[56] - The company's investment in Hicreative Pharmaceuticals (stock code: 688302) had an initial cost of RMB 33,811,556.98 and a final book value of RMB 108,602,565.12[62] - The company raised RMB 790,866,217.58 through a non-public stock issuance in 2023, with RMB 514,450,400 used during the reporting period and RMB 278,170,200 remaining unused[64] - The company's fundraising account balance as of June 30, 2023, was RMB 198,170,181.87[64] - The total balance of the company's raised funds as of June 30, 2023, is RMB 198,170,181.87, distributed across multiple bank accounts[65] - The company has pre-invested RMB 307,221,893.63 of self-raised funds into the raised funds projects and partial issuance expenses, which will be replaced by raised funds[65] - The company has temporarily supplemented its working capital with RMB 80 million from idle raised funds, with a maximum limit of RMB 200 million approved for this purpose[65] - The company has used idle raised funds for cash management, achieving a cumulative cash income of RMB 2,103,720.16 during the reporting period[65] - The investment progress of the long-acting oral hypoglycemic drug HSK7653's Phase III clinical research and registration project in China is 35.50%, with RMB 14,024.85 invested in the current period[67] - The investment progress of the new peripheral neuropathic pain treatment drug HSK-16149 capsule's Phase II/III clinical research and registration project in China is 100.00%, with RMB 12,406.66 invested in the current period[67] - The investment progress of the post-marketing re-evaluation project of Acetyl-L-Carnitine Hydrochloride Tablets in China is 70.97%, with RMB 4,013.53 invested in the current period[67] - The investment progress of the supplementary working capital and bank loan repayment project is 85.71%, with RMB 21,000 invested in the current period[67] - Total funds raised amounted to 82,073.71 million RMB, with 51,445.04 million RMB already utilized[68] - The company used 307,221,893.63 RMB of self